News

Equinix, NVIDIA & Together AI Accelerate Enterprise AI Inference

EQIX, DLR, WELL

EQIX teams with NVIDIA and Together AI on Inference Exchange, aiming to speed enterprise AI deployment with flexible, efficient infrastructure.

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN, ASND, BBIO

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

How NESR's 3B3 Strategy Offers a Clear Path to Long-Term Expansion

NESR, NOV, FET

National Energy Services' 3B3 strategy targets a $3 billion revenue run rate in three years through contract growth, market expansion and technology investments.

Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

MRNA, SNY, GSK, MRK

MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.

ChargePoint CEO says 50% stock surge 'is the beginning of the momentum'

The infrastructure company is toward the end of a three-year business plan that has boosted revenue and significantly cut the company's losses.

Carney claps back at Lutnick, says Canada will resume trade talks 'when the Americans are ready'

Canada has retaliated against President Donald Trump's 50% tariffs with "dollar for dollar" duties on U.S. goods, which are set to take effect next week.

One of Trump's Favorite Stocks Just Reported Blowout Earnings

DELL

On multiple occasions this year, President Donald Trump has publicly shown his support for Dell Technologies (NYSE: DELL), telling Americans to “go out and buy a Dell computer” as recently as July 6. In doing so, he has shone a light on one of the best-performing stocks over the

Nvidia strikes $12.9bn deal to buy AI platform Hugging Face

NVDA, NVDAN, NVDACL, NVD, NVDD, AI, 1NVDA, 4NVDA, 0R1I, 918422, NVDAUS, NVDA0, NVDA1, NVDACL1, NVDACL0

The deal gives Nvidia control of a leading open-source AI platform and developer community.

Big lessons from 12 stock exits, including Cramer's biggest-ever disappointment

2026

For stock investors, 2026 has meant constantly adjusting to geopolitical and economic pressures — and most importantly, protecting profits.

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

KYMR, ARVN, NRIX

KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.